Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Bologna – page 75

906 clinical trials in Bologna, Italy across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Bologna at a glance
906
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

906 trials in Bologna

Open in trial search

Plasma cell myeloma

Not recruiting

Study Comparing Selinexor, Pomalidomide, and Dexamethasone with Elotuzumab, Pomalidomide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:European Myeloma Network B.V.

Neoplasm

Not recruiting

Study of MCLA-129 with Chemotherapy and Osimertinib for Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Genmab A/S

Partial seizures

Not recruiting

Study on PRAX-628 for Adults with Focal Epilepsy Taking 1 to 3 Anti-Seizure Medications

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:PRAX-628
  • Sponsor:Praxis Precision Medicines Inc.

B-cell lymphoma

Not recruiting

Study of Loncastuximab Tesirine for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma or High-Grade B-Cell Lymphoma After CAR T-Cell Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Loncastuximab Tesirine
  • Sponsor:Humanitas Mirasole S.p.A.

Chondrosarcoma

Not recruiting

Study of INBRX-109 (ozekibart) compared to placebo in adults with unresectable or metastatic chondrosarcoma - a rare bone cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acetylcysteine
  • Sponsor:Inhibrx Biosciences Inc.

Hodgkin's disease+6

Not recruiting

Study of Cobolimab and Dostarlimab for Children and Young Adults with Newly Diagnosed or Relapsed/Refractory Tumors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Cobolimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Dermatitis atopic

Not recruiting

Study on the Safety and Effectiveness of Upadacitinib and Dupilumab for Children Aged 2 to 12 with Moderate to Severe Atopic Dermatitis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Dupilumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Acute lymphocytic leukaemia

Not recruiting

Study on Imatinib and Chemotherapy Combination for Children with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Crisantaspase
  • Sponsor:Universita Degli Studi Di Milano Bicocca

Anaplastic large cell lymphoma T- and null-cell types+2

Not recruiting

Study of Romidepsin and Drug Combination for Young Patients with Peripheral T-Cell Lymphomas Before Stem Cell Transplantation

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Romidepsin
  • Sponsor:Fondazione Italiana Linfomi Ets

B-cell lymphoma

Not recruiting

Study of Acalabrutinib Alone or with Rituximab for Patients with Relapsed/Refractory Marginal Zone Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Acerta Pharma B.V.

Neuroendocrine carcinoma metastatic

Not recruiting

Study of durvalumab, carboplatin and etoposide combination therapy for patients with metastatic large-cell neuroendocrine lung cancer who have not received previous treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:GOIRC Gruppo Oncologico Italiano Di Ricerca Clinica

Crohn's disease

Not recruiting

Study on Guselkumab for Healing in Crohn's Disease Patients

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Bologna

What the registry says about research in the country

01 Hematological Disorders

Innovative research focusing on Immune Thrombocytopenia and various forms of blood cancers including Acute Myeloid Leukemia and Multiple Myeloma. These trials aim to evaluate novel therapeutic approaches and combination treatments.

  • Blood Disorders
  • Leukemia Research
  • Immunology Studies

Studies include evaluation of new compounds and their safety profiles in treating various blood-related conditions.

02 Gastrointestinal Research

Comprehensive studies on inflammatory bowel conditions, focusing on Crohn's Disease and Ulcerative Colitis. Research aims to develop more effective treatments for patients with moderate to severe disease activity.

  • Inflammatory Bowel Disease
  • Treatment Response
  • Disease Management

Trials evaluate both induction therapy and long-term treatment options for gastrointestinal conditions.

03 Neurological Conditions

Investigation of treatments for sleep disorders including Narcolepsy and Idiopathic Hypersomnia, along with research into Chronic Inflammatory Demyelinating Polyneuropathy.

  • Sleep Disorders
  • Neurological Diseases
  • Treatment Safety

Focus on developing safer and more effective therapies for various neurological conditions.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.